BioSpace News Archive

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9th at 11:30 a.m. Eastern Time to discuss its financial results for the third quarter of 2022.

Pleno Inc., a multi-omic instrument platform company revolutionizing biological target detection for clinical testing and biomedical research, announced that Jason Trachewsky has joined the company as Vice President of Software, and Professor Nambi Seshadri, Ph.D. has joined as Chairman of Pleno’s Scientific Advisory Board.

Expansion Therapeutics, Inc. today announced the appointment of Raymond J. Kelleher, M.D., Ph.D., to its Board of Directors representing Cormorant Asset Management.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso, President and Chief Executive Officer of Precision BioSciences (the “Company”) under the Company’s 2021 Employment Inducement Incentive Award Plan.

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review.

BeiGene today announced significant progress in efforts to unlock global opportunities for BRUKINSA® (zanubrutinib) with recent regulatory approvals in six Latin American countries.

Nutriband Inc today announced that its subsidiary, 4P Therapeutics LLC has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc.

Sannova Analytical, LLC (“Sannova”), a leading contract research organization (“CRO”) that provides bioanalytical testing and analytical chemistry services to innovative pharmaceutical and biotechnology companies, is pleased to announce Jason Apter as its new Chief Executive Officer.

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2022 (“Reporting Period”).

Ikena Oncology, Inc. today announced a poster presentation highlighting preclinical data on the company’s novel TEAD inhibitor, IK-930, at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 26-28, 2022, in Barcelona, Spain.